High prevalence of cytotoxin positive Helicobacter pylori in patients unrelated to the presence of peptic ulcers in Japan

Gut

Volumn 41, Issue 4, 1997, Pages 463-468

  Ogura, K ^a   Kanai, F ^a   Maeda, S ^a   Yoshida, H ^a   Ogura, M ^a   Lan, K H ^a   Hirota, K ^b   Kawabe, T ^a   Shiratori, Y ^a   Omata, M ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Mito Saiseikai Hospital   (Japan)

Author keywords

Gastritis; Helicobacter pylori; Stomach; Ulcer; VacA

Indexed keywords

CYTOTOXIN; IMMUNOGLOBULIN G;

ADULT; ANTIBODY DETECTION; ARTICLE; CHRONIC GASTRITIS; DUODENUM ULCER; FEMALE; HELICOBACTER PYLORI; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; STOMACH ULCER;

EID: 9844260054     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.41.4.463     Document Type: Article

References (37)

1. Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, Miyazaki T, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992; 102: 760-6.
2. Graham DY, Adam E, Klein PD, Evans DJ Jr, Evans DG, Hazell SL, et al. Epidemiology of Campylobacter pylori infection. Gastroenterol Clin Biol 1989; 13: 84-88.
3. Marshall BJ, Goodwin CS, Warren JR, Murray R, Bloncow ED, Blackbourn SJ, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; ii: 1437-42.
4. Hosking SW, Ling TKO, Chung SC, Yung MY, Cheng AF, Sung JJ, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomized controlled trial. Lancet 1994; 343: 508-10.
5. Breuer KB, Armstrong D, Goebell H, Arnold R, Classen M, Fisher M, et al. Smoking as a risk factor for duodenal ulcer relapse. RUDER Study Group. Z. Gastroenterol 1995; 33: 509-12.
6. Anda RF, Williamson DF, Escobedo LG, Remington PL. Smoking and the risk of peptic ulcer disease among women in the United States. Arch Intern Med 1990; 150: 1437-41.
7. Leoci C, Ierardi E, Chiloiro M, Piccioli E, Di matteo G, Misciagna G, et al. Incidence and risk factors of duodenal ulcer. A retrospective cohort study. J Clin Gastroenterol 1995; 20: 104-9.
8. Levenstein S, Prantera C, Varvo V, Scribano ML, Berto E, Spinella S, et al. Patterns of biologic and psychologic risk factors in duodenal ulcer patients. J Clin Gastroenterol 1995; 21: 110-7.
9. Sipponen P, Aarynen M, Kaariainen I, Kettunen P, Helske T, Seppala K. Chronic antral gastritis, Lewis(a+) phenotype, and male sex as factors in predicting coexisting duodenal ulcer. Scand J Gastroenterol 1989; 24: 581-8.
10. Chuong JJ, Fisher RL, Chuong RL, Spiro HM. Duodenal ulcer. Incidence, risk factors, and predictive value of plasma pepsinogen. Dig Dis Sci 1986; 31: 1178-84.
11. Leunk RD, Johnson PT, David BC, Kraft WG, Morgan DR. Cytotoxic activity in broth-culture filtrates, of Campylobacter pylori. J Med Microbiol 1988; 26: 93-9.
12. Fox JG, Correa P, Taylor NS, Thompson N, Fontham E, Janney F, et al. High prevalence and persistence of cytotoxin-positive Helicobacter pylori strains in a population with high prevalence of atrophic gastritis. Am J Gastroenterol 1992; 87: 1554-60.
13. Cover TL, Dooley CP, Blaser MJ. Characterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity. Infect Immun 1990; 58: 603-10.
14. Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem 1992; 267: 10570-5.
15. Ghiara P, Marchetti M, Blaser MJ, Tummuru MK, Cover TL, Segal ED, et al. Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease. Infect Immun 1995; 63: 415460.
16. Leunk RD, Ferguson MA, Morgan DR, Low DE, Simor AE. Antibody to cytotoxin in infection by Helicobacter pylori. J Clin Microbiol 1990; 28: 1181-4.
17. Leunk RD. Production of a cytotoxin by Helicobacter pylori. Rev Infect Dis 1991; 13: S686-9.
18. Tee W, Lambert JR, Dwyer B. Cytotoxin production by Helicobacter pylori from patients with upper gastrointestinal tract diseases. J Clin Microbiol 1995; 33: 1203-5.
19. Cover TL, Cao P, Murthy UK, Sipple MS, Blaser MJ. Serum neutralizing antibody response to the vacuolating cytotoxin of Helicobacter pylori. J Clin Invest 1992; 90: 913-8.
20. Hirai M, Azuma T, Ito S, Kato T, Kohli Y, Fujiki N. High prevalence of neutralizing activity to Helicobacter pylori cytotoxin in serum of gastric-carcinoma patients. Int J Cancer 1994; 56: 56-60.
21. Atherton JC, Cao P, Peek RJ, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995; 270: 17771-7.
22. Cover TL, Tummuru MK, Cao P, Thompson SA, Blaser MJ. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains. J Biol Chem 1991; 269: 10566-73
23. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-7.
24. Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988; 85: 5409-13
25. Kawamata O, Yoshida H, Hirota K, Yoshida A, Kawaguchi R, Shiratori Y, et al. Nested-polymerase chain reaction for the detection of Helicobacter pylori infection with novel primers designed by sequence analysis of urease A gene in clinically isolated bacterial strains. Biochem Biophys Res Commun 1996; 219: 266-72.
26. Phadnis SH, Ilver D, Janzon L, Normark S, Westblom TU. Pathological significance and molecular characterization of the vacuolating toxin gene of Helicobacter pylori. Infect Immun 1994; 62: 1557-65.
27. Schmitt W, Haas R. Genetic analysis of the Helicobacter pylori vacuolating cytotoxin: structural similarities with the IgA protease type of exported protein. Mol Microbiol 1994; 12: 307-19.
28. Telford JL, Ghiara P, Dell'Oreo M, Comanducci M, Burroni D, Bungnoli M, et al. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J Exp Med 1994; 179: 1653-8.
29. Figura N, Guglielmetti P, Rossolini A, Barberi A, Cusi G, Musmanno RA, et al. Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only. J Clin Microbiol 1989; 27: 225-6.
30. Pereira IA, Glupczynski Y, Goossens H, Burette A, Butzler JP. Neutralising antibodies to the vacuolating toxin of Helicobacter pylori in gastritis only and peptic ulcer patients. Int J Med Microbiol Virol Parasitol Infect Dis 1993; 280: 197-202.
31. Hochuli E, Dobeli H, Schacher A. New metal chelate adsorbent selective for proteins and peptides containing neighbouring histidine residues. J Chromatogr 1987; 411: 177-84.
32. Manetti R, Massari P, Burroni D, de Bernard D, Marchini A, Olivieri R, et al. Helicobacter pylori cytotoxin: importance of native conformation for induction of neutralizing antibodies. Infect Immun 1995; 63: 4476-80.
33. Xiang Z, Censini S, Bayeli PF, Telford JL, Figura N, Rappuoli R, et al. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun 1995; 63: 94-8.
34. Maeda S, Ogura K, Ishitobi M, Kanai F, Yoshida H, Ota S, et al. Diversity of Helicobacter pylori vacA gene in Japanese strains high cytotoxin activity type S1 is dominant in Japan [abstract]. Gastroenterology 1996; 110: A182.
35. Health and Welfare Statistics Office. Table on mortality. Journal of Health and Welfare Statistics 1995; 42: 404.
36. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-31.
37. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995; 269: 496-512.